Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma

A feasibility study in Japanese population

Tomoki Ueda, Rioko Iino, Kenji Yokoyama, Shinichiro Okamoto, Keiko Asakura, Yuiko Tsukada, Jo Ishizawa, Eri Matsuki, Yasuo Ikeda, Yutaka Hattori

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM). Twentyfive newly diagnosed patients received double or single ASCT with high-dose melphalan (200 mg/m2). Two months after stem cell infusion, if the patients failed to achieve a near-complete response, thalidomide was administered at 200 mg/day until disease progression or occurrence of intolerable adverse events. Seventeen patients were in partial response or minimal response after ASCT and received thalidomide alone. Their median progression- free survival (PFS) from ASCT was 17.4 months, and the median overall survival (OS) was 42.9 months. Some patients with normal karyotype experienced durable disease stabilization for over 5 years. Five patients who exhibited high-risk chromosomal changes such as t(4;14) or deletion of chromosome 13 or 17 showed very short PFS and OS compared with those who did not. Observed grade 3 or 4 toxicities included infection in three patients, hematological toxicities in three, and gastrointestinal toxicities in two, but there was no grade 3 or higher peripheral neuropathy, probably due to appropriate dose modifications. This long-term prospective study is the first to demonstrate the feasibility of post-ASCT thalidomide therapy in Japanese patients with MM.

Original languageEnglish
Pages (from-to)477-484
Number of pages8
JournalInternational Journal of Hematology
Volume96
Issue number4
DOIs
Publication statusPublished - 2012 Oct

Fingerprint

Thalidomide
Feasibility Studies
Multiple Myeloma
Transplants
Population
Therapeutics
Disease-Free Survival
Survival
Chromosomes, Human, Pair 13
Chromosomes, Human, Pair 17
Melphalan
Autologous Transplantation
Peripheral Nervous System Diseases
Karyotype
Disease Progression
Stem Cells
Clinical Trials
Prospective Studies
Infection

Keywords

  • Autologous hematopoietic stem cell transplantation
  • High-risk myeloma
  • Multiple myeloma
  • Post-transplantation therapy
  • Thalidomide

ASJC Scopus subject areas

  • Hematology

Cite this

Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma : A feasibility study in Japanese population. / Ueda, Tomoki; Iino, Rioko; Yokoyama, Kenji; Okamoto, Shinichiro; Asakura, Keiko; Tsukada, Yuiko; Ishizawa, Jo; Matsuki, Eri; Ikeda, Yasuo; Hattori, Yutaka.

In: International Journal of Hematology, Vol. 96, No. 4, 10.2012, p. 477-484.

Research output: Contribution to journalArticle

Ueda, Tomoki ; Iino, Rioko ; Yokoyama, Kenji ; Okamoto, Shinichiro ; Asakura, Keiko ; Tsukada, Yuiko ; Ishizawa, Jo ; Matsuki, Eri ; Ikeda, Yasuo ; Hattori, Yutaka. / Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma : A feasibility study in Japanese population. In: International Journal of Hematology. 2012 ; Vol. 96, No. 4. pp. 477-484.
@article{7aede9d260ac4bb6b6984173102c01ce,
title = "Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma: A feasibility study in Japanese population",
abstract = "In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM). Twentyfive newly diagnosed patients received double or single ASCT with high-dose melphalan (200 mg/m2). Two months after stem cell infusion, if the patients failed to achieve a near-complete response, thalidomide was administered at 200 mg/day until disease progression or occurrence of intolerable adverse events. Seventeen patients were in partial response or minimal response after ASCT and received thalidomide alone. Their median progression- free survival (PFS) from ASCT was 17.4 months, and the median overall survival (OS) was 42.9 months. Some patients with normal karyotype experienced durable disease stabilization for over 5 years. Five patients who exhibited high-risk chromosomal changes such as t(4;14) or deletion of chromosome 13 or 17 showed very short PFS and OS compared with those who did not. Observed grade 3 or 4 toxicities included infection in three patients, hematological toxicities in three, and gastrointestinal toxicities in two, but there was no grade 3 or higher peripheral neuropathy, probably due to appropriate dose modifications. This long-term prospective study is the first to demonstrate the feasibility of post-ASCT thalidomide therapy in Japanese patients with MM.",
keywords = "Autologous hematopoietic stem cell transplantation, High-risk myeloma, Multiple myeloma, Post-transplantation therapy, Thalidomide",
author = "Tomoki Ueda and Rioko Iino and Kenji Yokoyama and Shinichiro Okamoto and Keiko Asakura and Yuiko Tsukada and Jo Ishizawa and Eri Matsuki and Yasuo Ikeda and Yutaka Hattori",
year = "2012",
month = "10",
doi = "10.1007/s12185-012-1166-y",
language = "English",
volume = "96",
pages = "477--484",
journal = "International Journal of Hematology",
issn = "0925-5710",
publisher = "Springer Japan",
number = "4",

}

TY - JOUR

T1 - Post-transplant consolidation therapy using thalidomide alone for the patients with multiple myeloma

T2 - A feasibility study in Japanese population

AU - Ueda, Tomoki

AU - Iino, Rioko

AU - Yokoyama, Kenji

AU - Okamoto, Shinichiro

AU - Asakura, Keiko

AU - Tsukada, Yuiko

AU - Ishizawa, Jo

AU - Matsuki, Eri

AU - Ikeda, Yasuo

AU - Hattori, Yutaka

PY - 2012/10

Y1 - 2012/10

N2 - In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM). Twentyfive newly diagnosed patients received double or single ASCT with high-dose melphalan (200 mg/m2). Two months after stem cell infusion, if the patients failed to achieve a near-complete response, thalidomide was administered at 200 mg/day until disease progression or occurrence of intolerable adverse events. Seventeen patients were in partial response or minimal response after ASCT and received thalidomide alone. Their median progression- free survival (PFS) from ASCT was 17.4 months, and the median overall survival (OS) was 42.9 months. Some patients with normal karyotype experienced durable disease stabilization for over 5 years. Five patients who exhibited high-risk chromosomal changes such as t(4;14) or deletion of chromosome 13 or 17 showed very short PFS and OS compared with those who did not. Observed grade 3 or 4 toxicities included infection in three patients, hematological toxicities in three, and gastrointestinal toxicities in two, but there was no grade 3 or higher peripheral neuropathy, probably due to appropriate dose modifications. This long-term prospective study is the first to demonstrate the feasibility of post-ASCT thalidomide therapy in Japanese patients with MM.

AB - In order to test for improved survival following autologous transplantation (ASCT), we conducted a prospective clinical trial of post-ASCT thalidomide therapy in Japanese patients with multiple myeloma (MM). Twentyfive newly diagnosed patients received double or single ASCT with high-dose melphalan (200 mg/m2). Two months after stem cell infusion, if the patients failed to achieve a near-complete response, thalidomide was administered at 200 mg/day until disease progression or occurrence of intolerable adverse events. Seventeen patients were in partial response or minimal response after ASCT and received thalidomide alone. Their median progression- free survival (PFS) from ASCT was 17.4 months, and the median overall survival (OS) was 42.9 months. Some patients with normal karyotype experienced durable disease stabilization for over 5 years. Five patients who exhibited high-risk chromosomal changes such as t(4;14) or deletion of chromosome 13 or 17 showed very short PFS and OS compared with those who did not. Observed grade 3 or 4 toxicities included infection in three patients, hematological toxicities in three, and gastrointestinal toxicities in two, but there was no grade 3 or higher peripheral neuropathy, probably due to appropriate dose modifications. This long-term prospective study is the first to demonstrate the feasibility of post-ASCT thalidomide therapy in Japanese patients with MM.

KW - Autologous hematopoietic stem cell transplantation

KW - High-risk myeloma

KW - Multiple myeloma

KW - Post-transplantation therapy

KW - Thalidomide

UR - http://www.scopus.com/inward/record.url?scp=84868010336&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868010336&partnerID=8YFLogxK

U2 - 10.1007/s12185-012-1166-y

DO - 10.1007/s12185-012-1166-y

M3 - Article

VL - 96

SP - 477

EP - 484

JO - International Journal of Hematology

JF - International Journal of Hematology

SN - 0925-5710

IS - 4

ER -